New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults

References

• Armstrong AW, Pathophysiology RC. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75(12):1393–1403.
   PubMed Web of Science ®Google Scholar
• O’Neill JL, Feldman SR. Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc). 2010;46(5):351–360.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Chiricozzi A, et al. The Risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments.Vaccines (Basel). 2020 [Published 2020 Dec 2];8(4):728. DOI:10.3390/vaccines8040728.
   PubMed Web of Science ®Google Scholar
• Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12(13):2041–2054.
   PubMed Web of Science ®Google Scholar
• Calcipotriene and Betamethasone. Lexi-Drugs. Hudson, OH: lexicomp, 2023. http://online.lexi.com. Updated Jan 12, 2022. Accessed Jan 9, 2023.
   Google Scholar
• Tapinarof. Lexi-Drugs. Hudson, OH: lexicomp, 2023. https://online.lexi.com./ Updated Nov 4, 2022. Accessed Jan 9, 2023.
   Google Scholar
• Pixley JN, Schaetzle T, Feldman SR. A review of topical roflumilast for the treatment of plaque psoriasis [published online ahead of print, 2022 Nov 24]. Ann Pharmacother. 2022;10600280221137750. DOI:10.1177/10600280221137750
   Web of Science ®Google Scholar
• Roflumilast (Topical). Lexi-Drugs Hudson, OH: Lexicomp, 2023. online.lexi.com/ Updated Nov 30, 2023. Accessed Jan 9, 2023.
   Google Scholar
• Otezla (APREMILAST) FDA approval history. Drugs.com. https://www.drugs.com/history/otezla.html. Accessed Jan 16, 2023.
   Google Scholar
• Apremilast. Lexi-drugs. Hudson, OH: Lexicomp, 2023. http://on.line.lexi.com/ Updated Dec 17, 2022. Accessed Dec 17, 2023.
   Google Scholar
• U.S. Food and Drug Administration Approves Sotyktu™ (Deucravacitinib), Oral treatment for adults with moderate-to-severe plaque psoriasis. News. https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis/default.aspx. Accessed Feb 5, 2023.
   Google Scholar
• Deucravacitinib. Lexi-Drugs. Hudson, OH: lexicomp, 2023. http://online.lexi.com/. Updated Jan 5, 2023. Accessed Jan 9, 2023.
   Google Scholar
• Farbstein M Can-fite announces positive top-line results from piclidenoson phase III COMFORTTM study in moderate to severe psoriasis. Business Wire. Jun 29, 2022. Accessed Jan 29, 2023. https://www.businesswire.com/news/home/20220629005222/en/%C2%A0Can-Fite-Announces-Positive-Top-Line-Results-from-Piclidenoson-Phase-III-COMFORT%E2%84%A2-Study-in-Moderate-to-Severe-Psoriasis.
   Google Scholar
• Tofacitinib. Lexi-Drugs. Hudson, OH: lexicomp. https://online.lexi.com/ Updated Jan 14 2023. Accessed Jan 14, 2023.
   Google Scholar
• Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm((R)) - and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017 Mar;176(3):615–623. DOI:10.1111/bjd.14947.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Barker J, Boehncke W-H, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018 Oct;Suppl 32:3–14. 10.1111/jdv.15218.
   Web of Science ®Google Scholar
• Stein Gold L, Green LJ, Dhawan S, et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021:20(4):420–425. doi:10.36849/JDD.5653.
   PubMed Web of Science ®Google Scholar
• Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022 Oct;87(4):800–806. DOI:10.1016/j.jaad.2022.06.1171.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229–239.
   PubMed Web of Science ®Google Scholar
• Cordoro KM. Roflumilast for chronic plaque psoriasis. JAMA. 2022;328(11):1049–1050.
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004;12(12):2233–2247. DOI:10.1016/j.str.2004.10.004
   PubMed Web of Science ®Google Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018 Published 2018 Oct 17;9:1048. DOI:10.3389/fphar.2018.01048.
   PubMed Web of Science ®Google Scholar
• Psomadakis CE, Han G. New and emerging topical therapies for psoriasis and atopic dermatitis. J Clin Aesthet Dermatol. 2019 Dec;12(12):28–34.
   PubMedGoogle Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2022;88(1):40–51. DOI:10.1016/j.jaad.2022.08.061.
   PubMed Web of Science ®Google Scholar
• Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018 Oct;179(4):853–862. DOI:10.1111/bjd.16798.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Br J Dermatol. 2015 Oct;173(4):949–961. doi:10.1111/bjd.14018.
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015 Aug 8;386(9993):552–561. DOI:10.1016/S0140-6736(14)62113-9.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Pinter A, Selmer J, et al. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/betamethasone dipropionate cream versus suspension/Gel. J Drugs Dermatol. 2022 Mar 1;21(3):242–248. DOI:10.36849/JDD.661.
   PubMedGoogle Scholar
• Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb). 2022 Oct;12(10):2217–2231. DOI:10.1007/s13555-022-00794-y.
   PubMed Web of Science ®Google Scholar
• FDA Approves Wynzora® Cream for Plaque Psoriasis. National Psoriasis Foundation. Accessed Jan 9, 2023. https://www.psoriasis.org/advance/fda-approves-wynzora-cream-plaque-psoriasis/
   Google Scholar
• Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021 Dec 9;385(24):2219–2229. DOI:10.1056/NEJMoa2103629.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022Sep 20;328(11):1073–1084. DOI:10.1001/jama.2022.15632.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Full prescribing information: zORYVE (roflumilast) cream, for topical use. Published 2022. Accessed Oct 31, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf
   Google Scholar
• Takeiri A, Tanaka K, Shioda A, et al. Lack of mutagenicity of SMD-502, a new vitamin D3 analog for topical application, in skin and liver of gpt delta transgenic mice and in GDL1 cells. Genes Environ. 2012;34(3):107–114. DOI:10.3123/jemsge.34.107
   Google Scholar
• Shimizu K, Kawase A, Haneishi T, et al. Novel vitamin D3 antipsoriatic antedrugs: 16-En-22-oxa-1α,25-(OH)2D3 analogs. Bioorg Med Chem. 2006;14(6):1838–1850. DOI:10.1016/j.bmc.2005.10.034
   PubMed Web of Science ®Google Scholar
• Watanabe H, Hatakeyama S, Tazumi K, et al. Synthetic studies of vitamin D analogs. XXII. Synthesis and antiproliferation activity of putative metabolites of 1 alpha, 25-dihydroxy-22-oxavitamin D3. Chem Pharm Bull (Tokyo). 1996;44(12):2280–2286.
   PubMed Web of Science ®Google Scholar
• Takeiri A, Tanaka K, Harada A, et al. Giemsa-stained pseudo-micronuclei in rat skin treated with vitamin D3 analog, pefcalcitol. Genes Environ. 2017;39:17. Published 2017 Jun 1. DOI:10.1186/s41021-017-0077-9.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029. DOI:10.1016/j.cellsig.2014.05.014
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888–897.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529–1538.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:906349.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• SM H. Deucravacitinib: first Approval. Drugs. 2022;82(17):1671–1679.
   PubMed Web of Science ®Google Scholar
• Le AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813–822.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–352.
   PubMed Web of Science ®Google Scholar
• Kim LS, Wu JJ, Han G. Deucravacitinib for psoriasis. Curr Dermatol Rep. 2021;10(1):1–5.
   Web of Science ®Google Scholar
• Catlett IM, Aras U, Hansen L, et al. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023:16(1);151–164. DOI:10.1111/cts.13435.
   PubMed Web of Science ®Google Scholar
• Myers Squibb B. SOTYKTUTM (deucravacitinib) tablets, for oral use: uS prescribing information. 2022. https://packageinserts.bms.com/pi/pi_sotyktu.pdf. Accessed 12 Sep 2022.
   Google Scholar
• Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010–20.e8. DOI:10.1016/j.jaci.2021.11.001
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Merighi S, Varani K, et al. A3 Adenosine Receptors as Modulators of Inflammation: from Medicinal Chemistry to Therapy. Med Res Rev. 2018;38(4):1031–1072.
   PubMed Web of Science ®Google Scholar
• Ighani A, Georgakopoulos JR, Yeung J. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2020 Aug;155(4):400–410. DOI:10.23736/S0392-0488.20.06643-2.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Loewe R, Mrowietz U, et al. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119–126. DOI:10.1111/jdv.15922.
   PubMed Web of Science ®Google Scholar
• Falkvoll S, Gerdes S, Mrowietz U. Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: results of a prospective study. J Dtsch Dermatol Ges. 2019 Sep;17(9):906–912.
   Google Scholar
• Treatments in phase 1 trials. The National Psoriasis Foundation.National Psoriasis Foundation. https://www.psoriasis.org/treatments-in-phase-1-trials/. Accessed Jan 19, 2023
   Google Scholar
• Treatments in phase 2 trials. The National Psoriasis Foundation.National Psoriasis Foundation. https://www.psoriasis.org/treatments-in-phase-2-trials/. Accessed Jan 19, 2023
   Google Scholar
• Yentzer BA, Feldman SR. Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. J DermatolTreat. 2009;20(4):238–240.
   Google Scholar
• Bashyam AM, Cuellar-Barboza A, Masicampo EJ, et al. Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use. J Am Acad Dermatol. 2020;83(6):1773–1775.
   PubMed Web of Science ®Google Scholar
• Oussedik E, Cardwell LA, Patel NU, et al. An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. Bioorganic & Medicinal Chemistry Jama Dermatol. 2017;153(9):932–934.
   PubMed Web of Science ®Google Scholar